Dr. Martin Gleave, MD, FRCSC, FACS
Dr. Gleave is a Distinguished Professor and Chairman of the Department of Urologic Sciences at the University of British Columbia (UBC); Co-Founder and Director of the Vancouver Prostate Center, now a UBC and National Centre of Excellence; and a British Columbia Leadership Chair. He has published 480 papers with >35,000 citations, has an H-Index of 97,and attracted >$100M in research funding.Dr. Gleave is a clinician-scientist and urologic surgeon whose clinical practice focuses onurologic oncology in a multi-disciplinary environment at the leading edge of assessing new technologies and treatments across both localized and advanced cancers. His researchcharacterizes molecular mechanisms mediating treatment resistance in cancer, focusing onadaptive survival responses that drive acquired treatment resistance, and designingcombination co-targeting strategies to create conditional lethality and improve cancer control.He patented several anti-cancer drugs and in 2001 founded OncoGenex Pharmaceuticals todevelop OGX-011 and OGX-427, inhibitors of cytoprotective chaperones clusterin and Hsp27now in Phase III and Phase II trials world-wide. He has co-founded several other companiesincluding Sitka Pharma, TRiADD, and Sustained Therapeutics.Dr. Gleave is the recipient of numerous awards, including the Richard Williams Award from the AUA in 2017, the Barringer Medal from the American Association of GU Surgeons; the EugeneFuller Award from the American Urological Association in 2013; the Aubrey Tingle Prize fromthe Michael Smith Foundation for Health Research; and the NCIC William Rawls Award forcontributions to cancer control in Canada; He was appointed a Distinguished University Scholar at UBC in 2003 and awarded a BC Leadership Chair in 2005. Dr Gleave was awardedthe 2006 BC Biotech Award for Innovation and Achievement, and the 2007 BC InnovationCouncil Frontiers in Research Award.
Friday, May 18
11:00 AM – 11:30 AM
Friday, May 18
1:00 PM – 3:00 PM